The global liver cancer therapeutics market size was estimated to be USD 4.48 billion in 2023 and is expected to reach at USD 33.79 billion by 2034 with a CAGR of 20.16% during the forecast period 2024-2034. Growing prevalence of liver cancer, surge in investments for the development of novel therapies, rising government awareness initiatives for cancer, increasing demand for effective & advanced liver cancer therapeutics, growing research & development activities, surge in launch of advanced therapies, rising approvals by regulatory bodies, and increasing number of clinical trial procedures by key market players are some of the key factors boosting the market growth.
Increasing number of awareness campaigns for liver cancer are being run, which lays the way for patient education and the significance of liver cancer treatments is predicted to boost the market growth during the forecast period. For instance, in July 2022, In collaboration with the Qatar Red Crescent, the Qatar Cancer Society (QCS) initiated the 'Protect Yourself' campaign to enhance awareness about liver cancer. The campaign includes various workshops and presentations, with a specific focus on increasing awareness among workers' centers.
By type, hepatocellular carcinoma (HCC) was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to rising prevalence of hepatocellular carcinoma, growing research & development activities, increasing demand for liver cancer therapeutics, and surge in regulatory approvals. For instance, in February 2023, Genoscience Pharma has been granted Orphan Drug Designation by the Food and Drug Administration (FDA) for ezurpimtrostat as a treatment for hepatocellular carcinoma (HCC). Ezurpimtrostat, also known as GNS561, is a novel autophagy inhibitor, the first of its kind in human trials, and its anti-cancer effects are associated with the inhibition of PPT-1. Additionally, cholangiocarcinoma is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cholangiocarcinoma, rising research & development activities, and surge in collaborations within market players.
By therapy, targeted therapy was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to the increasing adoption of personalized medicine and rising prevalence of cancer. Additionally, immunotherapy is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and surge in approvals by regulatory bodies. For instance, in October 2022, The United States has granted approval for AstraZeneca's Imjudo (tremelimumab) when used alongside Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), which is the prevalent form of liver cancer.
By route of administration, intravenous was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to increasing adoption of intravenous route for chemotherapy, and growing research & development activities for the manufacturing of advanced therapies. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for self-administration of medications, increasing launch of new products, and rising clinical trials procedures. For instance, in September 2022, Eisai and Merck & Co., Inc. have unveiled the initial outcomes of the conclusive analysis of the Phase 3 LEAP-002 study, which examines the combination of LENVIMA (a receptor tyrosine kinase inhibitor developed by Eisai) and KEYTRUDA (an anti-PD-1 therapy by Merck & Co., Inc.) compared to LENVIMA alone. This study aims to evaluate the effectiveness as a primary treatment for patients with inoperable hepatocellular carcinoma (uHCC).
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to the surge in number of patients with liver cancer, rising focus on development of new treatments, and increasing approvals by regulatory bodies. For instance, in October 2022, Innovent Biologics, Inc. is content to announce the approval by China's National Medical Products Administration (NMPA) of the supplementary New Drug Application (sNDA) for CYRAMZA® (ramucirumab) intended for patients diagnosed with hepatocellular carcinoma. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the surge in adoption of prescription-based medications and rising number of retail pharmacies across the globe.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing of liver cancer, growing launch of novel products, rising awareness regarding the disease, surge in demand of advanced treatment procedures, increasing research & development activities for the development of novel therapeutics, and growing number of clinical trial procedures. For instance, in April 2023, The phase III IMbrave050 clinical trial unveiled at the AACR Annual Meeting 2023 demonstrated that the utilization of atezolizumab (Tecentriq) and bevacizumab (Avastin) as adjuvant therapy enhanced the recurrence-free survival of patients with hepatocellular carcinoma (HCC) after surgical resection or ablation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of hepatocellular carcinoma, rising focus on development of innovative therapies, and increasing approvals by regulatory bodies. For instance, in January 2022, Merck has obtained conditional approval for its drug Keytruda as a treatment for liver cancer, supported by positive outcomes from its second confirmatory study. Keytruda demonstrated a 21% reduction in the risk of death compared to a placebo among patients with hepatocellular carcinoma in Asia.
Increasing number of awareness campaigns for liver cancer are being run, which lays the way for patient education and the significance of liver cancer treatments is predicted to boost the market growth during the forecast period. For instance, in July 2022, In collaboration with the Qatar Red Crescent, the Qatar Cancer Society (QCS) initiated the 'Protect Yourself' campaign to enhance awareness about liver cancer. The campaign includes various workshops and presentations, with a specific focus on increasing awareness among workers' centers.
By type, hepatocellular carcinoma (HCC) was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to rising prevalence of hepatocellular carcinoma, growing research & development activities, increasing demand for liver cancer therapeutics, and surge in regulatory approvals. For instance, in February 2023, Genoscience Pharma has been granted Orphan Drug Designation by the Food and Drug Administration (FDA) for ezurpimtrostat as a treatment for hepatocellular carcinoma (HCC). Ezurpimtrostat, also known as GNS561, is a novel autophagy inhibitor, the first of its kind in human trials, and its anti-cancer effects are associated with the inhibition of PPT-1. Additionally, cholangiocarcinoma is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cholangiocarcinoma, rising research & development activities, and surge in collaborations within market players.
By therapy, targeted therapy was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to the increasing adoption of personalized medicine and rising prevalence of cancer. Additionally, immunotherapy is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and surge in approvals by regulatory bodies. For instance, in October 2022, The United States has granted approval for AstraZeneca's Imjudo (tremelimumab) when used alongside Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), which is the prevalent form of liver cancer.
By route of administration, intravenous was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to increasing adoption of intravenous route for chemotherapy, and growing research & development activities for the manufacturing of advanced therapies. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for self-administration of medications, increasing launch of new products, and rising clinical trials procedures. For instance, in September 2022, Eisai and Merck & Co., Inc. have unveiled the initial outcomes of the conclusive analysis of the Phase 3 LEAP-002 study, which examines the combination of LENVIMA (a receptor tyrosine kinase inhibitor developed by Eisai) and KEYTRUDA (an anti-PD-1 therapy by Merck & Co., Inc.) compared to LENVIMA alone. This study aims to evaluate the effectiveness as a primary treatment for patients with inoperable hepatocellular carcinoma (uHCC).
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global liver cancer therapeutics market in 2023 owing to the surge in number of patients with liver cancer, rising focus on development of new treatments, and increasing approvals by regulatory bodies. For instance, in October 2022, Innovent Biologics, Inc. is content to announce the approval by China's National Medical Products Administration (NMPA) of the supplementary New Drug Application (sNDA) for CYRAMZA® (ramucirumab) intended for patients diagnosed with hepatocellular carcinoma. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the surge in adoption of prescription-based medications and rising number of retail pharmacies across the globe.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing of liver cancer, growing launch of novel products, rising awareness regarding the disease, surge in demand of advanced treatment procedures, increasing research & development activities for the development of novel therapeutics, and growing number of clinical trial procedures. For instance, in April 2023, The phase III IMbrave050 clinical trial unveiled at the AACR Annual Meeting 2023 demonstrated that the utilization of atezolizumab (Tecentriq) and bevacizumab (Avastin) as adjuvant therapy enhanced the recurrence-free survival of patients with hepatocellular carcinoma (HCC) after surgical resection or ablation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of hepatocellular carcinoma, rising focus on development of innovative therapies, and increasing approvals by regulatory bodies. For instance, in January 2022, Merck has obtained conditional approval for its drug Keytruda as a treatment for liver cancer, supported by positive outcomes from its second confirmatory study. Keytruda demonstrated a 21% reduction in the risk of death compared to a placebo among patients with hepatocellular carcinoma in Asia.
Segmentation: Liver Cancer Therapeutics Market Report 2022 - 2033
Liver Cancer Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Hepatoblstoma
- Others
Liver Cancer Therapeutics Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
Liver Cancer Therapeutics Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Intravenous
- Oral
Liver Cancer Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Liver Cancer Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Liver Cancer Therapeutics Market: Type Estimates & Trend Analysis
8. Liver Cancer Therapeutics Market: Therapy Estimates & Trend Analysis
9. Liver Cancer Therapeutics Market: Route of Administration Estimates & Trend Analysis
10. Liver Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Liver Cancer Therapeutics Market
13. Europe Global Liver Cancer Therapeutics Market
14. Asia Pacific Global Liver Cancer Therapeutics Market
15. Latin America Global Liver Cancer Therapeutics Market
16. MEA Global Liver Cancer Therapeutics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi SA
- Eisai Co. Ltd
- Exelixis Inc.
- Bayer AG
- Pfizer Inc.
- AbbVie Inc.
- Johnson & Johnson
- Celsion Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.48 Billion |
| Forecasted Market Value ( USD | $ 33.79 Billion |
| Compound Annual Growth Rate | 20.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
